We’ve recently updated our valuation analysis.

Vaccitech Valuation

Is VACC undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VACC?

Other financial metrics that can be useful for relative valuation.

VACC key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Sales Ratio vs Peers

How does VACC's PS Ratio compare to its peers?

The above table shows the PS ratio for VACC vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average3.4x
HOWL Werewolf Therapeutics
4.3x-7.8%US$89.4m
ORTX Orchard Therapeutics
5x51.4%US$91.7m
SPRO Spero Therapeutics
1.7x36.9%US$92.0m
DTIL Precision BioSciences
2.7x53.8%US$83.3m
VACC Vaccitech
3.2x-78.0%US$95.9m

Price-To-Sales vs Peers: VACC is good value based on its Price-To-Sales Ratio (3.2x) compared to the peer average (3.4x).


Price to Earnings Ratio vs Industry

How does VACC's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.6%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a22.6%
n/an/an/a
No more companies

Price-To-Sales vs Industry: VACC is good value based on its Price-To-Sales Ratio (3.2x) compared to the US Biotechs industry average (12.9x)


Price to Sales Ratio vs Fair Ratio

What is VACC's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VACC PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.2x
Fair PS Ratio0.05x

Price-To-Sales vs Fair Ratio: VACC is expensive based on its Price-To-Sales Ratio (3.2x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Share Price vs Fair Value

What is the Fair Price of VACC when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VACC's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VACC's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VACC forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.50
US$12.33
+393.4%
30.6%US$15.00US$7.00n/a3
May ’24US$2.32
US$12.67
+444.8%
31.8%US$16.00US$7.00n/a3
Apr ’24US$2.24
US$12.67
+465.5%
31.8%US$16.00US$7.00n/a3
Mar ’24US$3.15
US$19.67
+524.3%
14.6%US$23.00US$16.00n/a3
Feb ’24US$2.90
US$19.67
+578.2%
14.6%US$23.00US$16.00n/a3
Jan ’24US$2.35
US$19.67
+736.9%
14.6%US$23.00US$16.00n/a3
Dec ’23US$2.27
US$18.75
+726.0%
15.7%US$23.00US$16.00n/a4
Nov ’23US$2.76
US$18.75
+579.3%
15.7%US$23.00US$16.00n/a4
Oct ’23US$3.20
US$18.75
+485.9%
15.7%US$23.00US$16.00n/a4
Sep ’23US$4.00
US$18.75
+368.8%
15.7%US$23.00US$16.00n/a4
Aug ’23US$4.30
US$20.00
+365.1%
13.7%US$23.00US$16.00n/a4
Jul ’23US$4.61
US$20.00
+333.8%
13.7%US$23.00US$16.00n/a4
Jun ’23US$4.23
US$20.00
+372.8%
13.7%US$23.00US$16.00n/a4
May ’23US$5.38
US$21.25
+295.1%
8.4%US$23.00US$19.00US$2.324
Apr ’23US$5.19
US$21.25
+309.4%
8.4%US$23.00US$19.00US$2.244
Mar ’23US$6.77
US$24.00
+254.5%
9.8%US$28.00US$22.00US$3.154
Feb ’23US$9.34
US$24.00
+157.0%
9.8%US$28.00US$22.00US$2.904
Jan ’23US$11.11
US$24.00
+116.0%
9.8%US$28.00US$22.00US$2.354
Dec ’22US$12.33
US$24.50
+98.7%
9.4%US$28.00US$22.00US$2.274
Nov ’22US$13.81
US$24.50
+77.4%
9.4%US$28.00US$22.00US$2.764
Oct ’22US$15.55
US$24.50
+57.6%
9.4%US$28.00US$22.00US$3.204
Sep ’22US$14.70
US$24.50
+66.7%
9.4%US$28.00US$22.00US$4.004
Aug ’22US$14.56
US$24.50
+68.3%
9.4%US$28.00US$22.00US$4.304
Jul ’22US$15.61
US$24.50
+57.0%
9.4%US$28.00US$22.00US$4.614
Jun ’22US$14.80
US$24.50
+65.5%
9.4%US$28.00US$22.00US$4.234

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies